Considerations for the New Four-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB in the U.S.

Please note that Continuing Education Credits are not available for this webinar recording.

Presentation Slides
All Slides_Considerations for the New Four-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB in the U.S.

ACET Virtual Meeting

Proposed CDC guidance will be presented to the Advisory Committee on the Elimination of TB (ACET) Dec 14 or 15. This is a virtual meeting that is open to the public; typically 2 months before the meeting, the call-in information and agenda are ported in the Federal Register and ACET site, Advisory Council for the Elimination of Tuberculosis (ACET) | Committees | FAC | CDC.